Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data provide valuable insights for everyday practice. A long-term goal of systemic psoriasis therapy is to erase the inflammatory memory and thus achieve a sustainable cure. Several research projects have therefore focused on tissue-resident memory T-cells.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – Prostate abscess
- Asthma during pregnancy
Up to 40% suffer worsening of symptoms during pregnancy
- From symptom to diagnosis
Complicated renal cysts
- Atrial fibrillation
Anticoagulation after catheter ablation – for how long?
- Wound treatment and dermal defect coverage
Fish skin matrix for the treatment of complex ulcers
- Well-being of the medical profession in primary care
Findings of a nationwide survey in Switzerland
- Severe asthma and CRSwNP
Multidisciplinary collaboration between pneumology, allergology and ENT
- Myelofibrosis